Monopar Therapeutics (MNPR) Other Operating Expenses (2017 - 2025)
Monopar Therapeutics' (MNPR) quarterly Other Operating Expenses came in at -$1.0 in Q3 2025, down 100.0% quarter-over-quarter from $14.5 million in Q3 2017.
Monopar Therapeutics (MNPR) Other Operating Expenses (2017 - 2025) Analysis & Trends
Monopar Therapeutics has disclosed Other Operating Expenses across 2 years of filings, most recently posting -$1.0 for Q3 2025.
- Other Operating Expenses for Q3 2025 came in at -$1.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.0 (changed N/A YoY), and the FY2017 annual result was $14.5 million, changed N/A from the prior year.
- Other Operating Expenses came in at -$1.0 for Q3 2025 at Monopar Therapeutics, down from $14.5 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of -$1.0 in Q3 2025 to a low of -$1.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Monopar Therapeutics | 441.25 Mn | 441.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.00 |
| Sep 30, 2017 | 14.50 Mn |